EPCORITAMAB

Information current as at: 1 May 2025

Legend: Completed N In progress Not applicable N Yet to commence

Submission Details

Brand name:
  • Epkinly®
Pharmaceutical company:
ABBVIE PTY LTD
Condition/indication:
(therapeutic use)
  • Relapsed or refractory diffuse large B-cell lymphoma (RR DLBCL)
PBAC Submission type:
New PBS listing (Category 1)
Comment:
--
Related medicines:
--

Progress Details

Submission received for:
November 2024 PBAC meeting
Opportunity for consumer comment:
Open 31/07/2024 and close 25/09/2024 (see PBS Website)
PBAC meeting:
Held on 06/11/2024
PBAC outcome published:
Recommended (see PBAC Outcomes)
Notice of intent submitted:
08/01/2025
Lodgement of required documentation:
15/01/2025
Acceptance of complete documentation:
Accepted
Agreement to listing arrangements:
Commenced on 10/02/2025
Status:
Finalised
Government processes:
Commenced on 17/02/2025
Medicine listed on the PBS:
01/05/2025 (see PBS schedule)

Case ID: a931

Page last updated: 30 April 2025

v.9.18